Narrowband or Broadband UVB for Eczema? What a Randomized Trial Found

Dr. Arsy Editorial Team · November 9, 2026

Phototherapy is an office-based treatment option for some adults with moderate-to-severe atopic dermatitis. A recent randomized trial directly compared broadband and narrowband ultraviolet B, addressing a practical question earlier reviews could not settle.^[1][12][13]

Sixty-six treated participants

Thirty-two participants received at least one broadband treatment and 34 received narrowband UVB. Both groups continued topical therapy. At 12 weeks, mean EASI change was −8.1 with broadband and −8.9 with narrowband; the adjusted between-group difference was −0.7 with a credible interval spanning potentially better results in either direction. POEM, itch, quality of life and RECAP outcomes also showed no meaningful between-group differences.^[1]

Tolerability separated the groups

Four participants stopped broadband UVB because of adverse events, while none stopped narrowband UVB for that reason. The sample was too small to characterize uncommon risks or prove one modality is universally preferable. Treatment schedules, availability, skin type, other medicines and previous response remain relevant to a clinician’s recommendation.

Phototherapy is not ordinary sunlight

Clinical UVB uses controlled equipment, dosing and supervision. The trial does not support intentional sun exposure or tanning beds as substitutes. Burns, photoaging, medication interactions and long-term ultraviolet exposure require professional assessment. Eye protection and missed-treatment rules also matter.

Questions to take to a dermatology visit

• Why is phototherapy being considered after topical treatment?
• Which UVB type is available and what schedule is realistic?
• How will response and cumulative exposure be monitored?
• Which medicines or skin products affect photosensitivity?
• What happens if redness, burning or a flare follows treatment?

The trial supports similar average efficacy in its study population, with a tolerability signal favoring narrowband UVB. It does not replace an individualized prescription.^[13][17]

Moisturizer context

Dr. Arsy Moisturizer #003 supports cosmetic hydration for dry, sensitive and eczema-prone skin. It was not tested in the study above and does not reproduce the effects of prescription treatment, phototherapy or a care-delivery program.

Related research

• Online Eczema Care Versus Office Visits: What a 300-Patient Trial Found
• Can Topical Care Control Moderate Pediatric Eczema Long Term? The ROAD Study
• Ruxolitinib Cream in Children: What the 52-Week TRuE-AD3 Extension Shows
• Why a New Eczema Registry Matters Before It Produces Treatment Rankings
• Related eczema care research
• Related eczema care research

Research and clinical references

1. Narrowband versus broadband UVB randomized trial.
2. Online versus in-person atopic dermatitis care randomized trial.
3. ROAD study of long-term topical therapy in pediatric eczema.
4. TRuE-AD3 52-week ruxolitinib cream study in children.
5. Western Japan Atopic Dermatitis Registry design.
6. Teledermatology in atopic dermatitis systematic review.
7. Telemedicine in atopic dermatitis meta-analysis.
8. Teledermatology versus in-person follow-up randomized trial.
9. Web-based consultations for parents of children with eczema.
10. Direct-access online care randomized clinical trial.
11. Direct-access online care and quality of life trial.
12. Phototherapy for atopic eczema: Cochrane review.
13. AAD adult systemic therapy and phototherapy guideline.
14. AAD pediatric atopic dermatitis management guideline.
15. AAD adult topical therapy guideline.
16. AAP skin-directed management clinical report.
17. AAAAI/ACAAI atopic dermatitis guideline.
18. Ruxolitinib cream TRuE-AD1 and TRuE-AD2 phase 3 trials.
19. Pediatric ruxolitinib cream maximum-use trial.
20. Long-term proactive topical corticosteroid strategy trial.
21. Twice-weekly fluticasone maintenance in atopic dermatitis.
22. Topical corticosteroids for atopic eczema: Cochrane review.
23. Educational and psychological interventions for eczema: Cochrane review.
24. Atopic dermatitis outcome measurement harmonization.

Educational information only; not medical advice. Cited researchers and organizations do not endorse Dr. Arsy products.